A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator's Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
Clinical Trial Grant
Awarded By
Genmab US, Inc.
Start Date
February 5, 2026
End Date
January 8, 2031
Awarded By
Genmab US, Inc.
Start Date
February 5, 2026
End Date
January 8, 2031